@article{b05d5abb94664016b773c6a6033837fd,
title = "Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice",
abstract = "Apolipoprotein E genotype is an important risk factor of Alzheimer's disease, which is associated with the degeneration of distinct brain neuronal systems. In the present study we employed apolipoprotein E-deficient mice and human apolipoprotein E3 and apolipoprotein E4 transgenic mice on a null mouse apolipoprotein E background, to examine the extent to which distinct brain neuronal systems are affected by apolipoprotein E and the isoform specificity of this effect. This was pursued by histological and autoradiographic measurements utilizing neuron specific presynaptic markers. The results thus obtained revealed significant reductions in the levels of brain cholinergic and noradrenergic nerve terminals in young apolipoprotein E-deficient mice and no changes in brain dopaminergic nerve terminals. These cholinergic and noradrenergic presynaptic derangements were ameliorated similarly in human apolipoprotein E3 and apolipoprotein E4 transgenic mice. In the case of the cholinergic system, this resulted in complete reversal of the presynaptic deficits, whereas in the case of the noradrenergic neurons the amelioration was partial.These findings suggest that brain cholinergic and noradrenergic neurons are markedly more dependent on brain apolipoprotein E than brain dopaminergic neurons and that the isoform specificity of these effects is not apparent at a young age under non-challenged conditions. Copyright (C) 2000 IBRO.",
keywords = "Alzheimer's disease, Apolipoprotein E, Brain, Cholinergic, Dopaminergic, Transgenic mice",
author = "S. Chapman and T. Sabo and Roses, {A. D.} and Michaelson, {D. M.}",
note = "Funding Information: We thank Duke University and Glaxo Wellcome for kindly providing the transgenic mice. This work was supported partly by grants from the Joint German and Israeli research projects sponsored by the German and Israeli Ministries of Science (Grant 1626); from the Harry Stern National Center for Alzheimer{\textquoteright}s Disease and Related Disorders; from the Jo and Inez Eichenbaum Foundation and from the Revah-Kabelli Fund. D.M.M. is the incumbent of the Myriam Lebach Chair in Molecular Neurodegeneration.",
year = "2000",
month = may,
doi = "10.1016/S0306-4522(00)00087-7",
language = "אנגלית",
volume = "97",
pages = "419--424",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Ltd.",
number = "3",
}